Blood test could spare thousands of preemies from unnecessary antibiotics
NCT ID NCT06100614
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether adding a quick blood test for presepsin can safely reduce unnecessary antibiotic use in very preterm infants. Currently, over 85% of these babies get antibiotics right after birth, but only 1 in 70 actually has an infection. The study will enroll 900 infants born before 32 weeks to see if the test cuts antibiotic use by at least 30% without increasing missed infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Presepsin diagnostic test
- What this could lead to
- If successful, this test could help doctors avoid giving unnecessary antibiotics to many preterm infants, reducing side effects like bowel problems and allergies.
- What could go wrong
- The test might not be accurate enough, leading to missed infections or only a small reduction in antibiotic use. Results are from a single trial and need confirmation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-ONSET NEONATAL SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, North Holland, 1105 AZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.